|
| | lumateperone (Tosylate) Basic information |
| Product Name: | lumateperone (Tosylate) | | Synonyms: | 1-(4-Fluorophenyl)-4-[(6bR,10aS)-2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-1-butanone 4-methylbenzenesulfonate (1:1);Lumateperone(ITI-007);lumateperone (Tosylate);ITI 007;ITI-007;ITI 007;ITI007;LUMATEPERONE;1187020-80-9;ITI-722; ITI722; ITI 722; ITI-007; ITI007; ITI 007; LUMATEPERONE, CAPLYTA,;Lumateperone, Caplyta;lumateperone (Tosylate) ISO 9001：2015 REACH | | CAS: | 1187020-80-9 | | MF: | C31H36FN3O4S | | MW: | 565.7 | | EINECS: | | | Product Categories: | | | Mol File: | 1187020-80-9.mol |  |
| | lumateperone (Tosylate) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 25 mg/ml; DMF:PBS (pH 7.2) (1:7): 0.12 mg/ml; DMSO: 10 mg/ml; Ethanol: 1 mg/ml | | form | A solid |
| | lumateperone (Tosylate) Usage And Synthesis |
| Biochem/physiol Actions | Lumateperone tosylate (ITI-007) is an orally active, potent 5-HT2A antagonist, postsynaptic D2 antagonist, and serotonin transporter SERT inhibitor (Ki = 0.5, 32, 62 nM, respectively) with in vivo antipsychotic efficacy and no effect toward receptors associated with cognitive and metabolic side effects of antipsychotic drugs (e.g., H1, 5-HT2C, muscarinic). ITI-007 blocks DOI-induced headtwitch (ID50 = 0.09 mg/kg, po.) and D-AMPH-induced hyperlocomotion in mice (ID50 = 0.95 mg/kg, po.), while also acting as a partial agonist at presynaptic striatal D2 receptors. |
| | lumateperone (Tosylate) Preparation Products And Raw materials |
|
